Since the scDRS and in vitro results support a central role for IL1 signaling in endometriosis pathogenesis, we evaluated the effect of using anakinra to disrupt intercellular IL1 signaling in a validated mouse model of endometriosis‐associated pain.[33] Anakinra is a pharmacologically optimized recombinant version of interleukin‐1 receptor antagonist, the product of the IL1RN gene. Here, IL1A is linked to endometriosis.